twitter
en POLSKI
eISSN: 2719-3209
ISSN: 0023-2157
Klinika Oczna / Acta Ophthalmologica Polonica
Current issue Archive Videos Articles in press About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
4/2012
vol. 114
 
Share:
Share:
abstract:
Review article

New drug VEGF Trap-Eye – Eylea – and its use in the treatment of age-related macular degeneration, central retinal vein occlusion, diabetic macular edema, and choroidal neovascularization secondary to pathologic myopia

Robert Rejdak
1, 2
,
Małgorzata Szkaradek
2
,
Wesam Taslaq
2
,
Jakub J. Kałużny
3
,
Paweł Grieb
4
,
Anselm G. M. Jünemann
5

  1. Klinika Okulistyki Ogólnej, Katedra Okulistyki Uniwersytetu Medycznego w Lublinie
  2. Oddział Okulistyki Wojewódzkiego Szpitala Specjalistycznego im. F. Chopina w Rzeszowie
  3. Katedra Zdrowia Publicznego Collegium Medicum w Bydgoszczy Uniwersytetu Mikołaja Kopernika w Toruniu
  4. Zakład Farmakologii Doświadczalnej Instytutu Medycyny Doświadczalnej i Klinicznej Polskiej Akademii Nauk w Warszawie
  5. Klinik für Augenheilkunde, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen – Nürnberg, Erlangen
Online publish date: 2012/12/12
View full text Get citation
 
Vascular endothelial growth factor (VEGF) plays an important role in the pathogenesis of choroidal and retinal neovascularization. Anti-VEGF therapy changed the standard-of-care for ocular disease with neovascularisation. This article presents one promising new drug – VEGF Trap-Eye – and results of clinical trials evaluating its efficacy in the treatment of wet age-related macular degeneration, central retinal vain occlusion, diabetic macular edema and choroidal neovascularization secondary to pathologic myopia.
keywords:

vascular endothelial growth factor, VEGF Trap-Eye, Eylea, neovascularization

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.